Download Free Medical Management of Vitamin D Deficiency and Osteoporosis in Clinical Practice PowerPoint Presentation

Management of Vitamin D Deficiency and Osteoporosis in Clinical Practice PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Orthopaedics, which is titled "Management of Vitamin D Deficiency and Osteoporosis in Clinical Practice", to know about Management of Vitamin D Deficiency and Osteoporosis in Clinical Practice.

Tags : Orthopaedics, Management, Vitamin D, Deficiency, Osteoporosis, Clinical Practice

Published on : Aug 10, 2021 | Views : 2071 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Management of Vitamin D Deficiency and Osteoporosis in Clinical Practice M. Ali Karamat MBBS MRCP MD FRCP Consultant Physician and Honorary Senior Lecturer
Slide 2-

Overview of calcium homeostasis ¯ Ca2+ Ca2+ reabsorption & 1,25 DHD bone resorption Ca2+ availability
Slide 3-

National Osteoporosis Society Practical Guidelines. Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management. April 2013. Available at: http://www.nos.org.uk/document.doc?id=1352 Adapted from Fraser WD and Milan AM. Calcified Tissue Intl 2013; 92(2): 118-127. Vitamin D metabolism1,2 Metabolism of vitamin D
Slide 4-

Renal and extrarenal 1,25(OH)2D3 production serves endocrine, autocrine and paracrine functions Adapted from Dusso AS et al. Am J Physiol Renal Physiol 2005; 298(1): F8-28. Vitamin D is a multifunctional prohormone1
Slide 5-

National Osteoporosis Society Practical Guidelines. Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management. April 2013. Available at: http://www.nos.org.uk/document.doc?id=1352 Manifestations and symptoms of vitamin D deficiency1
Slide 6-

Adapted from IOM (Institute of Medicine). Dietary reference intakes for calcium and vitamin D. Washington; DTNAP; 2011. Adapted from Krall EA et al. N Engl J Med 1998; 321(26): 1777-83. Adapted from Arabi A et al. Bone 2010; 47(2): 408-12. Relationships between vitamin D and musculoskeletal health…….. Calcium absorption, bone mineral density (BMD) and osteomalacia1 Parathyroid hormone (PTH)2,3
Slide 7-

Adapted. from Bischoff-Ferrari HA et al. NEJM 2012; 367(1): 40-49 Adapted from Wang L et al. Circ Cardiovasc Qual Outcomes 2012; 5: 819-29. Relationships between vitamin D and… Fractures1 Cardiovascular risk2
Slide 8-

Persistently low Vitamin D status predisposes >75 year old women to fractures Swedish population based prospective study on BMD, falls, fractures N = 987, final report available for 640 women (>75 years old) Osteoporosis Int. 2014;25(Suppl 2). Abstract OC19
Slide 9-

Adapted from Hélard L et al. Dis Markers 2013; 35(5): 525-9. Relationship between vitamin D and length of hospital stay in the elderly1 Vitamin D insufficiency (≤50nmol/L) was associated with a 3-day longer hospital stay in elderly inpatients (15.2±8.2 vs. 12.1±7.0 days, p=0.017) 25OHD concentration inversely correlated (r=-0.14, p=0.028) and was inversely associated with length of stay (adjusted β=-0.07, 95% CI -0.14 to -0.02, p=0.043)
Slide 10-

Hyppönen E and Power C. Am J Clin Nutr 2007; 85(3): 860-8. Pearce SHS and Cheetham TD. BMJ 2010 Jan 11; 340: b5664. doi:10.1136/bmj.b5664. During the winter months there is inadequate sunlight in the UK to synthesise vitamin D1 Vitamin D insufficiency is common in the UK population2 Up to 50% of adult population in the UK will be vitamin D insufficient in winter and spring, with 16% having severe deficiency2 There is a significant north-south gradient in the prevalence of vitamin D insufficiency/deficiency1 In summer and autumn, 28% of adult population in Scotland will be vitamin D insufficient, with 8% having severe deficiency1
Slide 11-

National Osteoporosis Society Practical Guidelines. Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management. April 2013. Available at: http://www.nos.org.uk/document.doc?id=1352 https://www.gov.uk/government/publications/vitamin-d-advice-on-supplements-for-at-risk-groups http://www.nice.org.uk/nicemedia/live/13795/67630/67630.pdf The Chief Medical Officers defined at risk groups of vitamin D deficiency in clinical practice in February 20122
Slide 12-

Recommended thresholds for treatment National Osteoporosis Society Practical Guidelines. Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management. April 2013. Available at: http://www.nos.org.uk/document.doc?id=1352 Turpeinen U et al. Clin Chem 2003; 49(9): 1521-24. Janssen MJW et al. Clin Lab 2014; 60: Available at: http://www.clin-lab-publications.com/files/eaop/2014_01+02/130223-Janssen.pdf Knudsen CS et al. Clin Chem Lab Med 2012; 50(11): 1965-8. However, reliable routine serum 25OHD measurement tests may not be accurate below 30nmol/L. Evidence suggests tests have a limit of quantification ranging from 10–22.5nmol/L2-4 *Reference levels may differ in this range.
Slide 13-

EFSA Panel on Dietetic Products NaAN. Scientific opinion on the tolerable upper intake level of vitamin D. EFSA Journal 2012; 10(7): 2813. National Osteoporosis Society Practical Guidelines. Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management. April 2013. Available at: http://www.nos.org.uk/document.doc?id=1352 Recommended dosing strategy * European Food Safety Authority *In primary care, where rapid correction may often not be required, maintenance therapy may be started without the use of loading doses EFSA advises an upper limit of 4000 IU/day is safe for adults and children >11 years of age1
Slide 14-

Gallagher JC et al. Ann Intern Med 2012; 156: 425-37. 3200 IU/day is sufficient for restoring daily vitamin D concentrations no need for 20KIU when rapid repletion is not required Dose response to vitamin D3 treatment in healthy postmenopausal women was curvilinear and tended to plateau at approx. 112 nmol/L in patients receiving more than 3200 IU/day1
Slide 15-

CMOs’ letter February 2012* - The following groups of people are at risk of vitamin D deficiency: • All pregnant and breastfeeding women, especially teenagers and young women. Recommendations All UK Health Departments recommend: • All pregnant and breastfeeding women should take a daily supplement containing 10μg of vitamin D, to ensure the mother’s requirements for vitamin D are met and to build adequate foetal stores for early infancy. *specific to pregnancy and lactation Pregnancy & Lactation
Slide 16-

Vitamin D: increasing supplement use among at-risk groups NICE public health guidance 56 11 key recommendations Recommendation 1 Increase access to vitamin D supplements Recommendation 2 Clarify existing guidance Recommendation 3 Develop national activities to increase awareness about vitamin D Recommendation 4 Ensure a consistent multiagency approach Recommendation 5 Increase local availability of vitamin D supplements for at-risk groups Recommendation 6 Improve access to Healthy Start supplements Recommendation 7 Only test vitamin D status if someone has symptoms of deficiency or is at very high risk Recommendation 8 Ensure health professionals recommend vitamin D supplements Recommendation 9 Raise awareness among health, social care and other relevant practitioners of the importance of vitamin D Recommendation 10 Raise awareness of the importance of vitamin D supplements among the local population Recommendation 11 Monitor and evaluate the provision and uptake of vitamin D supplements NICE November 2014
Slide 17-

Vitamin D3 vs. calcium/vitamin D3 combination Not all patients need the added calcium the combination provides Guidelines state calcium/vitamin D3 should not be used as sources of vitamin D, given the high doses of calcium required if treating deficiency in combination1,2 Unlicensed The Advice from the Royal Pharmaceutical Society, the National Pharmacy Association and the MHRA is that wherever possible, a licensed medicine should be supplied against a prescription3 Recent publications have shown unlicensed preparations can have significant variances between actual content and label strength. One analysis showed variances in label claim versus actual from 8+ 2% to 210+ 29%4. Treatment of choice in vitamin D deficiency1 National Osteoporosis Society Practical Guidelines. Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management. April 2013. Available at: http://www.nos.org.uk/document.doc?id=1352 Data on file Internis Pharmaceuticals Ltd D2. http://www.gmc-uk.org/guidance/ethical_guidance.asp. Accessed October 2014 4. http://www.ncbi.nlm.nih.gov/pubmed/23364495 . *NOS – National Osteoporosis Society
Slide 18-

Variable content 14.3–171% of label content leading to poor control1 8–201% of label content2 3 cases of hypervitaminosis D, hypercalcaemia and renal insufficiency in patients taking oral vitamin D supplement3 Declared vitamin D3 content 600 IU per capsule vs. actual content approx. 880 times higher3 No medical information or pharmacovigilance No yellow card adverse event reporting Unregulated excipients No TSE certification Challenges with unlicensed unregulated supplements Data on file. Internis Pharmaceuticals Ltd. Garg S et al. J Nutr Health Aging 2013; 17(2): 158-61. Benemel S et al. Brit J Clin Pharmacol 2013; 76(5): 825-6. Evidence suggests vitamin D intoxication due to use of unlicensed supplements is not rare.3 Vitamin D supplements do not undergo quality control and may be dangerous to consumers’ health. Given preparations labeled ‘food’ are commonly used without medical prescription, their contents should be strictly regulated3 *TSE – transmissible spongiform encephalopathy
Slide 19-

Vitamin D is well known and has been widely used in clinical practice for many years1 Data on file. Internis Pharmaceuticals Ltd. IOM (Institute of Medicine). Dietary reference intakes for calcium and vitamin D. Washington; DTNAP; 2011. Adapted from Vieth R. Ann Epidemiol 2009; 19(7): 441-5. EFSA Panel on Dietetic Products NaAN. Scientific opinion on the tolerable upper intake level of vitamin D. EFSA Journal 2012; 10(7): 2813. Safety of vitamin D treatment in the licensed form Toxicity is most likely to occur in chronic overdosage where hypercalcaemia could result2 Doses above 10,000 IU/day are associated with toxicity2 Doses ≥50,000 IU/day for several weeks or months are frequently associated with toxicity, including documented hypercalcaemia2
Slide 20-

2.129. Incidences of High to Toxic 25-Hydroxy Vitamin D Levels amongst Users of a Direct-to-the-Public Blood Spot Vitamin D Testing Service Direct to Public Blood Spot Testing Service DBS Shea & Berg 69 users (1.5%) had 25OHD >220 nmol/l Only 2 under medical supervision 6 patients had 25OHD >500 nmol/l and were taking 11,000-100k IU/day Yet, 55% of users with 25OHD >220 nmol/l were taking 10KIU/day or less Conclusion: Highlights the fact that it is vital that public awareness is increased on the risks of self-administration and over-treatment. Asks: How many people are over supplementing unknowingly as they have not had their levels checked? Queen Mary University 23-25th April 2014
Slide 21-

Vitamin D2 Vitamin D2 as a lower tissue bioavailability especially after intermittent bolus dosing1 Vitamin D3 is the NOS recommended treatment of choice1 Metabolised Vitamin D treatment such as Alfacalcidol, one alpha and Calcitriol Restricted for use only in renal impairment2 Additional twice weekly serum calcium levels monitoring required Variable cost depending on dose response, other costs are calcium testing and HCP time as weekly testing is required Vitamin D2 & metabolised vitamin D treatments 1.http://www.nos.org.uk/page.aspx?pid=183&srcid=325- accessed Oct 2013 2. https://www.medicines.org.uk/emc/medicine/2449
Slide 22-

Reduction in risk of falls in elderly1 Reduction in risk of fractures in elderly2 Reduction in mortality3,4 Implicated beyond bone, ongoing research in: Bischoff-Ferrari HA et al. BMJ 2009; 339: b3692. doi:10.1136/bmj.b3692. Bischoff-Ferrari HA et al. NEJM 2012; 367(1): 40-49. Bjelakovic G et al. Cochrane Database Syst Rev 2011 Jul 6; (7): CD007470. doi: 10.1002/14651858.CD007470.pub2. Gotsman I et al. Eur J Heart Fail 2012;14(4): 357-66. Benefits of vitamin D treatment – overview Obesity Diabetes Cancer Multiple sclerosis This slide discusses off-label use. It is purely for the education of the medic speaker and not for wider dissemination to any audience. Hypertension Cardiovascular disease Autoimmune conditions
Slide 23-

High-dose vitamin D treatment reduced the risk of falling among older individuals by 19% This slide discusses off-label use. It is purely for the education of the medic speaker and not for wider dissemination to any audience. Adapted from Bischoff-Ferrari HA et al. BMJ 2009; 339: b3692. doi:10.1136/bmj.b3692. High-dose vitamin D treatment reduced risk of falls in the elderly1
Slide 24-

High-dose vitamin D treatment ≥800 IU/day (with or without calcium) reduced the risk of: Hip fractures by 30% in elderly patients ≥65 years of age Non-vertebral fractures by 14% in elderly patients ≥65 years of age Adapted from Bischoff-Ferrari HA et al. NEJM 2012; 367(1): 40-49. High-dose vitamin D treatment reduced risk of fractures in the elderly1 This slide discusses off-label use. It is purely for the education of the medic speaker and not for wider dissemination to any audience.
Slide 25-

Vitamin D3 decreased mortality significantly (RR 0.94, 95% CI 0.91–0.98; 74,789 participants, 32 trials) whereas vitamin D2, alfacalcidol, and calcitriol did not Adapted from Bjelakovic G et al. Cochrane Database Syst Rev 2011 Jul 6; (7): CD007470. doi: 10.1002/14651858.CD007470.pub2. Vitamin D3 treatment was associated with reduced mortality in elderly females1 This slide discusses off-label use. It is purely for the education of the medic speaker and not for wider dissemination to any audience.
Slide 26-

Adapted from Gotsman I et al. Eur J Heart Fail 2012;14(4): 357-66. Vitamin D treatment was associated with reduced mortality in heart failure patients1 Vitamin D deficiency is highly prevalent in HF patients and is a significant predictor of reduced survival Vitamin D treatment was independently associated with reduced mortality in HF patients (HR 0.68, 95% CI 0.54–0.85, p<0.0001) *HF – heart failure This slide discusses off-label use. It is purely for the education of the medic speaker and not for wider dissemination to any audience.
Slide 27-

Signs & symptoms associated with Hypercalcaemia Polyuria/polydipsia Constipation Gastric ulcer disease Muscle weakness Renal stones Bone pain
Slide 28-

Causes of hypercalcaemia Common Malignancy (metastatic via cytokines & humoral via PTH-rp) Primary and secondary hyperparathyroidism Rare Hyperthyroidism Thiazide diuretics
Slide 29-

Treatment of severe symptomatic hypercalcaemia Almost inevitably occurs in malignancy • Volume expansion Saline (care with CCF/RF) Furosemide • Administer iv bisphosphonate (pamidronate) In very rare and severe cases of hypercalcaemia (Ca2+ 4.5 – 5 mmol/L), haemodialysis may be used
Slide 30-

Overview of approved osteoporosis treatments in the UK1-3 IV, intravenous. All product SmPCs can be found at https://www.google.co.uk/?gfe_rd=cr&ei=jPzGVqnHEuPW8geKvq-IAg&gws_rd=ssl#q=emc Trademarks registered to companies as stated on trademark registry
Slide 31-

Overview of approved osteoporosis treatments in the UK1-3 National Osteoporosis Society website. Drug treatments for osteoporosis. Available at: https://www.nos.org.uk/ scans-tests-drugs/drug-treatments. Conbriza SmPC. Pfizer Ltd. 17/04/2014. Miacalcic SmPC. Novartis Pharmaceuticals UK Ltd. 09/12/2015. mAb, monoclonal antibody; PTH, parathyroid hormone; rh, recombinant human; SERM, selective estrogen receptor modulator. All product SmPCs can be found at https://www.google.co.uk/?gfe_rd=cr&ei=jPzGVqnHEuPW8geKvq-IAg&gws_rd=ssl#q=emc Trademarks registered to companies as stated on trademark registry
Slide 32-

Anti-fracture efficacy of approved treatments for postmenopausal women with osteoporosis*1 National Osteoporosis Guideline Group. Osteoporosis: Clinical Guideline for Prevention and Treatment. July 2010. Available at: https://www.shef.ac.uk/NOGG/NOGG_Executive_Summary.pdf. *When given with calcium and vitamin D. A=Recommendation based on meta-analysis of randomised controlled trials (RCT) or at least one RCT, nae, not adequately evaluated; rhPTH, recombinant human parathyroid hormone; # in subsets of patients only (post-hoc analysis).
Slide 33-

Bisphosphonates have been shown to prevent both vertebral and non-vertebral fractures1 Meta-analysis for alendronate relative to placebo resulted in a: RR of vertebral fracture of 0.56 (95% CI 0.46–0.68, 4 RCTs, n=7,039) RR of hip fracture of 0.62 (95% CI 0.40–0.98, 3 RCTs, n=7,455) RR of wrist fracture of 0.67 (95% CI 0.34–1.31, 4 RCTs, n=7,931) RR for other non-vertebral fractures of 0.81 (95% CI 0.68–0.97, 6 RCTs, n=9,973) Meta-analysis for etidronate relative to placebo resulted in a: RR of vertebral fracture of 0.40 (95% CI 0.20–0.83, 3 RCTs, n=341) RR of hip fracture of 0.50 (95% CI 0.05–5.34, 2 RCTs, n=180) RR for other non-vertebral fractures of 1.04 (95% CI 0.64–1.69; 4 RCTs, n=410) There were no data for wrist fracture Meta-analysis for risedronate relative to placebo resulted in a: RR of vertebral fracture of 0.61 (95% CI 0.50–0.75, 3 RCTs, n=2301) RR of hip fracture of 0.74 (95% CI 0.59–0.93, 3 RCTs, n=11,770) RR of wrist fracture of 0.68 (95% CI 0.43–1.08, 2 RCTs, n=2439) RR for other non-vertebral fractures of 0.76 (95% CI 0.64–0.91, 5 RCTs, n=12,399) NICE technology appraisal guidance TA160. October 2008. Available at: https://www.nice.org.uk/guidance/ta160.
Slide 34-

Bisphosphonates are considered first line treatment for the primary prevention of osteoporotic fragility fractures1 NICE technology appraisal guidance TA160. October 2008. Available at: https://www.nice.org.uk/guidance/ta160.
Slide 35-

Bisphosphonates are considered first line treatment for secondary prevention of osteoporotic fragility fractures1 NICE technology appraisal guidance TA161. October 2008. Available at: https://www.nice.org.uk/guidance/ta161.
Slide 36-

Bisphosphonate therapy is associated with poor adherence in the treatment of osteoporosis1 Both compliance and persistence are suboptimal for postmenopausal women undergoing bisphosphonate therapy for the treatment of osteoporosis 80% of patients are non-compliant within one year of bisphosphonate treatment initiation2 Imaz I et al. Osteoporosis Int 2010; 21: 1943–1951. Data on File. Internis Pharmaceuticals Ltd. D1 Few strategies attempting to improve adherence have demonstrated clinical outcomes – the design and development of new programmes or treatments to improve adherence to these drugs is needed
Slide 37-

At least one third of new bisphosphonate patients treated with tablets will not receive a further prescription1 Data on file. Internis Pharmaceuticals. 2015.
Slide 38-

GI side effects are the main reason for stopping oral bisphosphonate therapy1 Difficulty or discomfort in swallowing (dysphagia) is common, especially among elderly people, and the perceived potential for upper GI problems is a barrier to good long-term adherence In a normal clinical setting, GI adverse events are among the most common reasons for giving up oral bisphosphonate therapy Generic bisphosphonate formulations have been shown to be associated with an increase in upper GI adverse events, leading to therapy discontinuation Brandi M and Black D. Clin Cases Miner Bone Metab 2013; 120(3): 187–190. Length of contact of the tablet Reflux Gastric acid conditions Multiple factors contribute to the development of clinical GI effects and should be considered: The chemical formula of the molecule Lack of education on expected side effects
Slide 39-

Managing GI tolerability could be the key for your patients who discontinue alendronate therapy1,2 GI side effects are the most common reason for alendronate discontinuation2 Alendronate tablets can contribute to gastric irritability in a number of ways2,3 Brandi M and Black D. Clin Cases Miner Bone Metab 2013; 120(3): 187–190. Invernizzi M et al. Aging Clin Exp Res 2015; 27: 107–113. Accoto CG et al. Calcif Tissue Int 2012; 91: 325–334. Dyspepsia Dysphagia Oesophagitis Oesophageal ulcers Early tablet dissolution Slow transit time Acid reflux Hazardous reflux Less acidic More acidic